Luminespib is a selective heat shock protein 90 (Hsp90) inhibitor investigated for the treatment of various malignancies, including non-small cell lung cancer, melanoma, and prostate cancer. As an experimental… Read more
Luminespib is a selective heat shock protein 90 (Hsp90) inhibitor investigated for the treatment of various malignancies, including non-small cell lung cancer, melanoma, and prostate cancer. As an experimental therapeutic, this category provides essential tools for rigorous pharmaceutical analysis, including high-purity reference standards of the active pharmaceutical ingredient. Laboratories rely on these materials, alongside pharmacopeial and non-pharmacopeial impurities, to perform comprehensive impurity profiling and ensure strict quality control throughout drug development. Furthermore, the inclusion of stable isotope labelled compounds facilitates precise quantitative analysis, enabling researchers to conduct accurate method validation and metabolic studies. By utilizing these chemically characterized reference materials, analytical teams can successfully support the development and characterization of this potential oncology treatment.